Accelerating the Foundation

The deal between Roche and Foundation Medicine Inc. gives Foundation the capital and commercial reach necessary to maintain its first-mover advantage in cancer genome profiling and could help the company attain its goal of making the FoundationOne molecular tests standard of care for cancer significantly faster than it could on its own.

Foundation markets two cancer genome profiling tests: FoundationOne and FoundationOne Heme. Both are laboratory-developed tests (LDTs) that pinpoint altered genes from tumor samples and can be used to identify treatment options and clinical trials for cancer patients. ...